Rozlytrek® (entrectinib), the first tumour-agnostic therapy discovered for the treatment of patients with NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies. Rozlytrek have shown promising results across multiple tumour types, including cancer that has spread to the brain.
Rozlytrek® (entrectinib) is a tumour-agnostic oral medicine taken once-daily for the treatment of locally advanced or metastatic solid tumours that harbour NTRK1/2/3 or ROS1 gene fusions. Rozlytrek has the ability to block NTRK and ROS1 kinase activity and may result in the death of cancer cells with NTRK or ROS1 gene fusions. Rozlytrek represents to be the new effective treatment for patients with NTRK and ROS1 gene fusions even when their cancer has spread to the brain.
Some of the most common adverse reactions (≥20 percent) with Rozlytrek were fatigue, constipation, altered sense of taste (dysgeusia), swelling (oedema), dizziness, diarrhoea, nausea, nervous system disorders (dysaesthesia), shortness of breath (dyspnoea), anaemia, increased weight, increased blood creatinine, pain, cognitive disorders, vomiting, cough, and fever (pyrexia).
European Commission has granted Rozlytrek for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies.
